Advertisement

Picture BIO Deutschland Biotech Investors Day BID 2019 Würzburg 600x60px
Organisation › Details

InflaRx (Group)

InflaRx is a biopharmaceutical company focusing on the development of new therapeutics controlling the inflammatory response based on its proprietary technology.. InflaRx has developed a pipeline of first-in-class antibodies directed against the terminal complement component C5a. While IFX-1 focuses on the acute care space, its product candidates, IFX-2 and IFX-3, are being developed in chronic inflammatory disease indications. InflaRx was founded in 2007 and is headquartered in Jena, Germany, with long standing research collaborations in the US and China. The team consists of renowned experts in complement research and clinical acute care. InflaRx is privately owned and financed by bm-t Beteiligungsmanagement Thüringen Gmbh, KfW banking group and various international family offices. *

 

Period Start 2007-01-01 established
Products Industry anti-inflammatory drug
  Industry 2 IFX-1 (InflaRx)
Persons Person Riedemann, Niels C. (InflaRx 200803 Managing Director + founder)
  Person 2 Christ, Arnd (InflaRx 201506– CFO before Proteros + MediGene + NovImmune + Probiodrug + Hoechst)
     
Region Region Jena
  Country Germany
  Street 2 Winzerlaer Str.
  City 07745 Jena
    Address record changed: 2017-11-13
     
Basic data Employees n. a.
  Currency EUR
  Annual sales 108,000 (income, other, net, consolidated (2017) 2017-12-31)
  Profit -24,238,000 (2017-12-31)
  Cash 115,200,000 (2018-03-31)
     
    * Document for �About Section�: Merck & Co., Inc.. (1/11/16). "Press Release: Merck Acquires IOmet Pharma and Expands Immuno-Oncology Development Program". Kenilworth, NJ.
     
   
Record changed: 2018-10-31

Advertisement

Picture EBD Group BIO-Europe Spring 2019 BES Wien Partnering Opens 600x60px

More documents for InflaRx (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture BIO Deutschland Biotech Investors Day BID 2019 Würzburg 600x60px




» top